Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

Authors

Keywords

Journal

Volume -, Issue -, Pages -

Publisher

Oxford University Press (OUP)

Online

2017-12-07

DOI

10.1093/ndt/gfx350

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started